Extended Data Fig. 5: EGFR inhibitors increased the sensitivity of EGFRhigh liver cancer cells to FGFR inhibitors in vitro. | Nature

Extended Data Fig. 5: EGFR inhibitors increased the sensitivity of EGFRhigh liver cancer cells to FGFR inhibitors in vitro.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 5

a, b, Long-term colony formation assay of 11 liver cancer cell lines treated with the FGFR inhibitors AZD4547 (a) and BGJ398 (b). Cells were grown in the absence or presence of drugs at the indicated concentrations for 10–14 days, fixed and stained. cf, EGFRhigh liver cancer cell lines (SNU449, JHH1, Huh6 and SNU182) were treated with FGFR inhibitors (AZD4547 or BGJ398), EGFR inhibitor (gefitinib) or their combination at the indicated concentrations. Growth curves were determined by Incucyte live cell analyses. Data are mean ± s.e.m., n = 5. gl, FGFR inhibitors (AZD4547 or BGJ398) but not the FGFR4-specific inhibitor BLU-554 showed a synergistic effect with EGFR inhibitors in EGFRhigh liver cancer cells in vitro. Liver cancer cell lines with different EGFR expression levels were treated with FGFR inhibitors (AZD4547 or BGJ398), FGFR4-specific inhibitor (BLU-554), EGFR inhibitors (gefitinib or erlotinib) or their different combinations at the indicated concentrations. The cells were fixed and stained after 10–14 days. mo, SNU449 and JHH1 cells were treated with gefitinib (2.5 μM for SNU449; 0.625 μM for JHH1), BGJ398, sorafenib, or as a combination of two or three drugs. m, The cells were fixed, stained and photographed after 14 days. n, o, Quantification of three independent assays. Data are mean ± s.e.m., n = 3 independent experiments. P values were determined by two-sided unpaired Student’s t-test

Source data.

Back to article page